Clinical trials: Aromatase Inhibitor
Neoadjuvant Therapy
Aromatase Inhibitors Plus Chemotherapy vs Chemotherapy as Neoadjuvant Treatment in Postmenopausal HR(+) Breast Cancer
The investigators designed this study to investigate the effect of aromatase inhibitors (AI) plus chemotherapy versus chemotherapy as neoadjuvant treatment in postmenopausal hormone receptor-positive breast cancer.
- Trial name
- ACCN (NCT02769104)
- Testing
- Letrozole (Aromatase Inhibitors), AC*4-T*4
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Zhejiang Cancer Hospital
Breast Cancer Female, HER2-positive Breast Cancer
Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer
This study is a single-arm, open-label, phase II study, comparing the efficacy and safety of pyrotinib plus trastuzumab and aromatase inhibitors, in the treatment of HR (hormone receptor)+/HER2 (human epidermal growth factor…
- Conditions
- Breast Cancer Female, HER2-positive Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast, Metastatic Breast Cancer
- Trial name
- NCT04088110
- Testing
- Pyrotinib, Trastuzumab, Aromatase Inhibitors
- Where
- China
- Volunteers
- 77 people
- Sponsor
- Fuzhou General Hospital
Carpal Tunnel Syndrome (CTS) in Breast Cancer Patients
Laser Acupuncture on Carpal Tunnel Syndrome .
The study will be carried out on a total number of fifty-four females with age ranged 40 - 60 years old suffering from CTS post mastectomy ,the patients will be randomly assigned into two groups equal in number (27 patients for…
- Trial name
- NCT07405008
- Testing
- LASER acupuncture technique, Traditional physical therapy
- Where
- Egypt
- Volunteers
- 54 people
- Sponsor
- Cairo University
Musculoskeletal Symptoms, Breast Cancer
Evaluating the Efficacy of Structured Exercise Interventions in Alleviating Aromatase Inhibitor-Induced Arthralgia in Breast Cancer Survivors: a Pilot Study Protocol
Endocrine therapy represents a foundational approach for managing hormone receptor-positive breast cancer, with treatment typically spanning 5 to 10 years.
- Conditions
- Musculoskeletal Symptoms, Breast Cancer, Endocrine Therapy, Aromatase Inhibitors
- Trial name
- RE-MS (NCT06754293)
- Testing
- rehabilitation exercise
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Fudan University
Breast Cancer
Effect of Sukshma Vyayama Yoga on Aromatase Inhibitor-Induced Arthralgia in Breast Cancer Survivors
The purpose of this study is to investigate the efficacy of sukshma vyayama joint loosening yoga in improving aromatase inhibitor-induced arthralgia in post-menopausal breast cancer survivors and secondarily, to evaluate the…
- Trial name
- NCT04042870
- Testing
- Joint Loosening Yoga
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- AshtaYoga, LLC
Metastatic Breast Cancer
A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer
The reason for this study is to see if the drug abemaciclib in combination with nonsteroidal aromatase inhibitors (anastrozole or letrozole) is effective in participants with Hormone Receptor Positive (HR+), Human Epidermal…
- Trial name
- proMONARCH (NCT03988114)
- Testing
- Abemaciclib, Nonsteroidal Aromatase Inhibitor (NSAI)
- Where
- 119 sites in United States, Argentina and 7 more
- Sponsor
- Eli Lilly and Company
Advanced Breast Cancer
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer
The purpose of this study is to assess the safety and efficacy of alpelisib plus fulvestrant in men and postmenopausal women with hormone receptor (HR) positive, human epidermal growth factor 2 (HER2)-negative, advanced breast…
- Trial name
- NCT04524000
- Testing
- Alpelisib, Fulvestrant
- Where
- 15 sites in Japan
- Volunteers
- 24 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer, Musculoskeletal Disease
Placebo-controlled Trial With Vitamin D to Prevent Worsening/Relieve Aromatase Inhibitor-induced Musculoskeletal Symptoms in Breast Cancer Patients
The third generation oral aromatase inhibitors (AIs) are increasingly being used in the management of estrogen receptor positive breast cancer.
- Trial name
- NCT01809171
- Testing
- Vitamin D3
- Where
- Belgium
- Volunteers
- 15 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Breast Cancer
Changes in Breast Density and Blood Hormone Levels in Postmenopausal Women Receiving Anastrozole or Exemestane for Breast Cancer
RATIONALE: Studying changes in breast density and blood hormone levels in women receiving anastrozole or exemestane for breast cancer may help doctors learn more about the long-term effects of treatment and may help the study of…
- Trial name
- NCT00516698
- Testing
- polymorphism analysis, high performance liquid chromatography, laboratory biomarker analysis
- Where
- 180 sites in United States
- Volunteers
- 140 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Atrophic Vaginitis
Clinical Study of Vaginal Lactobacilli and Estriol (Gynoflor®) for Atrophic Vaginitis in Breast Cancer Patients
The purpose of this study is to assess the long term safety and efficacy of the vaginal application of Gynoflor®, an extremely low dosed estrogen therapy with lactobacilli, on atrophic vaginitis in postmenopausal breast cancer…
- Trial name
- Gynoflor (NCT01370551)
- Testing
- Estriol 0.03 mg, lyophylized lactobacillus
- Where
- 2 sites in Belgium, Germany
- Volunteers
- 16 people
- Sponsor
- Medinova AG
Osteoporosis, Osteoporosis Fracture
Breast Cancer Women on Aromatase Inhibitors Treatment
The main objective of the study is to improve the life quality of women treated with AI. Cohort B-ABLE is designed to evaluate musculoskeletal events derived of using AI in breast cancer women.
- Conditions
- Osteoporosis, Osteoporosis Fracture, Arthralgia Generalized
- Trial name
- B-ABLE (NCT03811509)
- Testing
- bisphosphonate
- Where
- Spain
- Volunteers
- 1,000 people
- Sponsor
- Parc de Salut Mar
Breast Cancer
Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer
The primary objective of Phase 1b will be to evaluate the safety and tolerability of TTI-101 when added to palbociclib and AI or fulvestrant administered orally to participants with hormone receptor-positive (HR+) human epidermal…
- Trial name
- NCT05384119
- Testing
- TTI-101, Palbociclib, Aromatase inhibitor (AI)
- Where
- 6 sites in United States
- Volunteers
- 6 people
- Sponsor
- Tvardi Therapeutics, Incorporated
Breast Cancer
Study of Faslodex +/- Concomitant Arimidex v Exemestane Following Progression on Non-steroidal Aromatase Inhibitors
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using fulvestrant, anastrozole, or exemestane may fight breast cancer by blocking the use of estrogen by the tumor cells or by lowering the amount…
- Trial name
- SoFEA (NCT00253422)
- Testing
- Anastrozole, Exemestane, Fulvestrant
- Where
- 2 sites in United Kingdom
- Volunteers
- 698 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Breast Cancer
Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding
The purpose of this study is to assess the efficacy, safety and tolerability of 2 dosing regimens of BIIB021 in combination with exemestane in women whose HR+ breast cancer had progressed following treatment with a nonsteroidal…
- Trial name
- NCT01004081
- Testing
- BIIB021, exemestane (Aromasin)
- Where
- 34 sites in United States, Australia and 2 more
- Volunteers
- 54 people
- Sponsor
- Biogen
Breast Cancer, Joint Pain
Curcumin in Reducing Joint Pain in Breast Cancer Survivors With Aromatase Inhibitor-Induced Joint Disease
This phase I trial studies how well curcumin works in reducing joint pain in patients who are breast cancer survivors and have joint disease caused by treatment with aromatase inhibitors.
- Trial name
- NCT03865992
- Testing
- Curcumin, Nanoemulsion, Quality-of-Life Assessment
- Where
- 4 sites in United States
- Volunteers
- 42 people
- Sponsor
- City of Hope Medical Center
Breast Cancer
Systemic Dickkopf-related Protein 1 (DKK1)During Estrogen Level Changes in Post-menopausal Breast Cancer Patients Treated With Aromatase Inhibitors
The investigators are hypothesizing that decreasing estrogen levels will cause serum DKK1 to peak, then decrease gradually as estrogens reach a new lower, but steady level.
- Trial name
- NCT01431872
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Arkansas
Hormone Receptor-positive Breast Cancer
Efficacy and Safety of Leuprorelin 3M in Premenopausal Women With Hormone Receptor-positive Breast Cancer
Leuprorelin, a LHRH agonist, acts as a potent inhibitor of gonadotropin secretion and is commonly used for the treatment of hormone-responsive prostate cancer, premenopausal HR+ breast cancer, endometriosis and uterine fibroids.
- Trial name
- NCT04891731
- Testing
- AI or TAM
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancer
Quality of Life in Chinese Postmenopausal HR(+) Early Breast Cancer (EBC) Patients During Adjuvant Aromatase Inhibitors(AIs) Treatment
The purpose of the study is to evaluate quality of life (Qol) in postmenopausal HR (+) EBC patients during adjuvant AIs treatment in terms of: the change of the trial outcome index (TOI) of the FACT-B questionnaire from baseline…
- Trial name
- BC Qol NIS (NCT01144572)
- Where
- 15 sites in China
- Volunteers
- 494 people
- Sponsor
- AstraZeneca
Breast Cancer
HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer.
The HOBOE study was amended in November 2009, and, after reaching enrollment of the first 500 patients, the study began recruiting premenopausal patients only.
- Trial name
- HOBOE (NCT00412022)
- Testing
- tamoxifen, triptorelin, letrozole
- Where
- 20 sites in Italy
- Volunteers
- 1,294 people
- Sponsor
- National Cancer Institute, Naples
Breast Cancer, Aromatase Inhibitors
Assessment of Cryotherapy's Analgesic Impact in Anti-aromatase-induced Arthralgia
The first aim of this comparative, randomized, prospective, multicenter study is to evaluate the analgesic effect at 6 weeks of whole-body cryotherapy, compared to placebo cryotherapy, in patients suffering from arthralgia under…
- Trial name
- CRYOMATASE (NCT05315011)
- Testing
- Whole-body cryotherapy
- Where
- 2 sites in France
- Volunteers
- 70 people
- Sponsor
- University Hospital, Montpellier